number of downloads : ?
language
eng
Author
Sato Shuichi Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Japan
Miyake Tatsuya Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Japan
ISHIHARA, Shunji Department of Internal Medicine II, Shimane University Faculty of Medicine
Subject
nonalcoholic; steatohepatitis; type 2 diabetes mellitus; sodium-glucose; cotransporter 2-inhibitor; dapagliflozin; open-label
Journal Title
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
Volume
87
Start Page
13
End Page
19
ISSN
0011-393X
ISSN(Online)
1879-0313
Published Date
2017
DOI
PubMed ID
Publisher
ELSEVIER SCIENCE INC
NII Type
Journal Article
OAI-PMH Set
Faculty of Medicine
Remark
Dapagliflozin was developed by AstraZeneca, who provided funding for publication fees and development of the manuscript, but did not play any other role in the study design; collection, analysis, and interpretation of data; writing of the manuscript; or the decision to submit the manuscript for publication. HT and YK have received honoraria from AstraZeneca K.K. Funding to pay for editorial support and the Open Access publication charges for this article were provided by AstraZeneca K.K. and Ono Pharmaceutical Co, Ltd. The authors have indicated that they have no other conflicts of interest regarding the content of this article.
このエントリーをはてなブックマークに追加